UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Clinical pharmacokinetics, 2014-01, Vol.53 (1), p.1-16

2014

Volltextzugriff (PDF)

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

European journal of clinical pharmacology, 2021-04, Vol.77 (4), p.527-537

2021

Volltextzugriff (PDF)

The effect of food on the absorption and pharmacokinetics of rivaroxaban

International journal of clinical pharmacology and therapeutics, 2013-07, Vol.51 (7), p.549-561

2013

Volltextzugriff (PDF)

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Journal of clinical pharmacology, 2013-03, Vol.53 (3), p.249-255

2013

Volltextzugriff (PDF)

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Journal of clinical pharmacology, 2007-02, Vol.47 (2), p.218-226

2007

Volltextzugriff (PDF)

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Thrombosis journal, 2013-06, Vol.11 (1), p.10-10

2013

Volltextzugriff (PDF)

Rivaroxaban: a new oral factor Xa inhibitor

Arteriosclerosis, thrombosis, and vascular biology, 2010-03, Vol.30 (3), p.376-381

2010

Volltextzugriff (PDF)

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Current medical research and opinion, 2008-10, Vol.24 (10), p.2757-2765

2008

Volltextzugriff (PDF)

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

British journal of clinical pharmacology, 2010-11, Vol.70 (5), p.703-712

2010

Volltextzugriff (PDF)

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Journal of clinical pharmacology, 2006-05, Vol.46 (5), p.549-558

2006

Volltextzugriff (PDF)

Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation

Drug metabolism and pharmacokinetics, 2013, Vol.28 (1), p.59-70

2013

Volltextzugriff (PDF)

Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients

DRUG METABOLISM AND PHARMACOKINETICS, 2013, Vol.28 (4), p.321-331

2013

Volltextzugriff (PDF)

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

Thrombosis and haemostasis, 2008, Vol.100 (3), p.453-461

2008

Volltextzugriff (PDF)

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

British journal of clinical pharmacology, 2013-09, Vol.76 (3), p.455-466

2013

Volltextzugriff (PDF)

Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics

AAPS open, 2022-11, Vol.8 (1), p.1-14, Article 16

2022

Volltextzugriff (PDF)

Conformal primary basis for Dirac spinors

Physical review. D, 2020-11, Vol.102 (10), Article 106025

2020

Volltextzugriff (PDF)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism

Journal of thrombosis and thrombolysis, 2020-07, Vol.50 (1), p.12-19

2020

Volltextzugriff (PDF)

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation

Drug safety, 2008, Vol.31 (1), p.67-77

2008

Volltextzugriff (PDF)

Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation

PloS one, 2011-04, Vol.6 (4), p.e17626

2011

Volltextzugriff (PDF)

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary circulation, 2019-04, Vol.9 (2), p.1-10

2019

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

British journal of clinical pharmacology, 2009-07, Vol.68 (1), p.77-88

2009

Volltextzugriff (PDF)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.805-814

2019

Volltextzugriff (PDF)

Generalized supergravity equations and generalized Fradkin-Tseytlin counterterm

The journal of high energy physics, 2019-05, Vol.2019 (5), p.1-19, Article 63

Mück, Wolfgang

2019

Volltextzugriff (PDF)

Photons in a ball

The European physical journal. C, Particles and fields, 2015-12, Vol.75 (12), p.1-9, Article 585

Mueck, Wolfgang

2015

Volltextzugriff (PDF)

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease

Pulmonary circulation, 2015-06, Vol.5 (2), p.296-304

2015

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(114)

Publikationsform

Artikel
(105)
Buchkapitel
(26)
Bücher
(2)
Reviews
(1)

Sprache

Englisch
(108)
Deutsch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects

The effect of food on the absorption and pharmacokinetics of rivaroxaban

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects

Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Rivaroxaban: a new oral factor Xa inhibitor

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation

Confirmation of Model-based Dose Selection for a Japanese Phase III Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients

Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics

Conformal primary basis for Dirac spinors

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation

Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling

Generalized supergravity equations and generalized Fradkin-Tseytlin counterterm

Photons in a ball

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease

Aktive Filter

Suchergebnisse filtern